Constellation Pharmaceuticals Granted Patent US12612390B2
Summary
The USPTO granted Patent US12612390B2 to Constellation Pharmaceuticals, Inc. on April 28, 2026. The patent covers novel compounds of Formula (I) and their pharmaceutical salts, which function as modulators of methyl modifying enzymes for treating diseases, disorders, and conditions associated with these enzymes. The application (No. 18140730) was filed on April 28, 2023, and contains 6 claims.
“Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO issued Patent US12612390B2 to Constellation Pharmaceuticals, Inc., covering novel compounds of Formula (I) and their pharmaceutical salts as modulators of methyl modifying enzymes. The patent also protects pharmaceutical compositions containing these compounds and methods for treating diseases associated with methyl modifying enzymes. CPC classifications include C07D 405/12, C07D 405/14, and A61P 35/00.
Pharmaceutical companies engaged in drug discovery targeting epigenetic or methyl-transferase pathways should monitor this patent portfolio to assess potential freedom-to-operate implications. Competitors developing compounds in the C07D chemical space for oncology applications may need to evaluate design-around strategies.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Modulators of methyl modifying enzymes, compositions and uses thereof
Grant US12612390B2 Kind: B2 Apr 28, 2026
Assignee
Constellation Pharmaceuticals, Inc.
Inventors
Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
Abstract
Provided are novel compounds of Formula (I):
and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
CPC Classifications
C07D 405/12 C07D 405/14 A61P 35/00
Filing Date
2023-04-28
Application No.
18140730
Claims
6
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.